Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | SARS-CoV-2 in multiple myeloma

Krina Patel • 5 May 2021
IMS 2021
Multiple Myeloma CAR-T

Multiple myeloma affects adaptive immunity with neoplastic plasma cells being unable to manufacture the polyclonal immunoglobulins required to fight infections. Additionally, myeloma treatment can raise immunodeficiency, especially during the initial months of treatment or during relapsed disease. In this video, Krina Patel, MD, MSc, MD Anderson Cancer Center, Houston, TX, talks on SARS-CoV-2 in multiple myeloma, highlighting strategies to mitigate negative outcomes. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Krina Patel

14:10
Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks
Krina Patel et al. • 10 Dec 2022
2:44
Real-world safety & efficacy of ide-cel in patients with multiple myeloma
Krina Patel • 26 Aug 2022
1:49
Rehabilitation needs of patients with multiple myeloma undergoing CAR-T therapy
Krina Patel • 26 Aug 2022
2:48
Can CAR-T therapy be used in conjunction with or instead of autologous transplantation in myeloma?
Krina Patel • 28 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals